Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist
Alexandra Litvinchuk(Hope Center for Neurological Disorders), David M. Holtzman(Hope Center for Neurological Disorders), Melissa Manis(Hope Center for Neurological Disorders), Carla M. Yuede(Washington University in St. Louis), Anil G. Cashikar(Washington University in St. Louis), Enmanuel J. Perez(Hope Center for Neurological Disorders), Eric Tycksen(Washington University in St. Louis), Sonnet S. Davis(Denali Therapeutics (United States)), Nga Bien‐Ly(Alector (United States)), Jason D. Ulrich(Hope Center for Neurological Disorders), Javier Remolina Serrano(Hope Center for Neurological Disorders), Gilbert Di Paolo(Denali Therapeutics (United States)), G. Travis Tabor(Hope Center for Neurological Disorders), Jing Guo(Qingdao University), Xin Bao(Weihai Maternal and Child Health Hospital), Karin Lin(Denali Therapeutics (United States)), Choonghee Lee(Hope Center for Neurological Disorders), Jung H. Suh(Denali Therapeutics (United States)), Megan E. Bosch(Hope Center for Neurological Disorders)
Cited by 133
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases
|Immunity|2017|3k
Alzheimer disease
|Nature Reviews Disease Primers|2021|2.4k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k